Johnson & Johnson Reports Strong Q1, Raises 2026 Guidance, and Increases Dividend for 64th Consecutive Year

summarizeSummary

Johnson & Johnson reported strong first-quarter results, raised its full-year 2026 financial guidance, and increased its quarterly dividend for the 64th consecutive year, signaling robust performance and shareholder commitment.

check_boxKey Events

• Strong Q1 2026 Financial Results

  Johnson & Johnson reported first-quarter 2026 sales of $24.1 billion, representing a 9.9% reported growth and 6.4% operational growth. Adjusted EPS for the quarter was $2.70.

• Raised Full-Year 2026 Guidance

  The company increased its full-year 2026 outlook, with estimated reported sales now projected at $100.3 billion to $101.3 billion (7.0% growth at midpoint) and adjusted EPS at $11.45 to $11.65 (7.1% growth at midpoint).

• 64th Consecutive Dividend Increase

  The Board of Directors declared a 3.1% increase in the quarterly dividend, raising it from $1.30 to $1.34 per share, marking the 64th consecutive year of dividend increases.

• Key Product Approvals Highlighted

  The company highlighted multiple game-changing approvals in the quarter, including ICOTYDE for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO for multiple myeloma, VARIPULSE Pro in Europe, and TECNIS PureSee Intraocular Lens in the U.S.

auto_awesomeAnalysis

Johnson & Johnson's latest 8-K filing signals robust financial health and a strong commitment to shareholder returns. The company reported solid first-quarter sales growth and, more importantly, raised its full-year 2026 guidance for both sales and adjusted EPS. This upward revision, coupled with the 64th consecutive annual dividend increase, demonstrates management's confidence in its operational performance and future cash flow generation. The announcement of multiple new product approvals further underpins the company's growth strategy, particularly in its Innovative Medicine and MedTech segments, which are crucial for long-term value creation.